Clinical trial
Hepsera Versus Hepsera Plus Lamivudine for Treatment of Chronic Hepatitis B in…
NCT00230477 · University of Washington, Other · Completed
Key facts
| NCT number | NCT00230477 |
|---|---|
| Title | Hepsera Versus Hepsera Plus Lamivudine for Treatment of Chronic Hepatitis B in Patients With Normal ALT |
| Official title | Efficacy of Adefovir Dipivoxil Versus Adefovir Dipivoxil Plus Lamivudine for the Treatment of Chronic Hepatitis B in Patients With Normal Baseline ALT |
| Lead sponsor | University of Washington, Other |
| Collaborators | Gilead Sciences Industry GlaxoSmithKline |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hepatitis B |
| Intervention type | Drug |
| Interventions | Hepsera, Hepsera and lamivudine |
| Enrollment | 19 |
| Start date | Apr 1, 2003 |
| Completion | Aug 1, 2007 |
| First posted | Sep 30, 2005 |
| Last update posted | Nov 15, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: